Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.
- None.
- None.
Insights
Analyzing...
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET.
A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
What is Arvinas presenting at the Guggenheim Healthcare Talks on February 11?
Who will represent Arvinas at the Oncology Day event?
How can I access the Arvinas presentation live on February 11?
What are the main clinical programs Arvinas is currently working on?
What is the focus of Arvinas as a biopharmaceutical company?
